Effect of single low-dose dexmedetomidine on ED50 of propofol for successful insertion of upper gastrointestinal endoscope

Effect of single low-dose dexmedetomidine on median effective dose (ED50) of propofol for successful insertion of upper gastrointestinal endoscope

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200055952

Enrollment

Unknown

Registered

2022-01-29

Start date

2022-01-29

Completion date

Unknown

Last updated

2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Experimental group:0.9%N.S + propofol

Control Group:single low-dose dexmedetomidine + propofol

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 65 years; 2. Patients who underwent gastroscopy and colonoscopy under anesthesia; 3. ASA is classified as grade I - II; 4. Body mass index (BMI): 18 - 30; 5. Mallampati is classified as grade I - II; 6. Fully understand the purpose and significance of this trial, voluntarily participate in this clinical trial, be able to read and understand the informed consent form, and voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Pregnant or lactating women; 2.Unable to walk without assistance; 3.Patients with bradycardia (heart rate <= 60 beats / min) or serious arrhythmia history or cardiac insufficiency history; 4.Clinical diagnosis of cognitive impairment in medical history; 5.Body weight greater than 100 kg; 6.Allergic to propofol, soy or glycerol components; 7.Previous adverse reactions of dexmedetomidine; 8.Previous diagnosis of acute or chronic renal impairment; 9.Serious liver damage leads to ascites and liver cirrhosis; 10.Benzodiazepines or opioids were used within 24 hours before gastrointestinal endoscopy; 11.Uncontrolled hypertension, myocardial infarction, ischemic cardiomyopathy or taking ß-Receptor blockers; 12.Patients with a history or possibility of difficult airway, such as obstructive sleep apnea syndrome; 13.Mouth opening < 3cm, radiation injury or tumor of neck, instability of cervical spine; 14.Combined with upper airway diseases, such as a history of upper respiratory tract infection within two weeks.

Design outcomes

Primary

Measure	Time frame
median effective dose (ED50) of propofol;	—

Countries

China

Contacts

Public ContactXue Fushan

Beijing Friendship Hospital, Capital Medical University

xuefushan@aliyun.com+86 10 63138761

Outcome results